News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,145 Results
Type
Article (41360)
Company Profile (266)
Press Release (684504)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204912)
Career Advice (2030)
Deals (35600)
Drug Delivery (120)
Drug Development (81525)
Employer Resources (174)
FDA (16483)
Job Trends (15016)
News (346886)
Policy (32788)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2587)
Accelerated approval (43)
Adcomms (25)
Allergies (158)
Alliances (49621)
ALS (192)
Alzheimer's disease (1734)
Antibody-drug conjugate (ADC) (362)
Approvals (16790)
Artificial intelligence (586)
Autoimmune disease (217)
Automation (49)
Bankruptcy (362)
Best Places to Work (11685)
BIOSECURE Act (20)
Biosimilars (202)
Biotechnology (175)
Bladder cancer (175)
Brain cancer (62)
Breast cancer (681)
Cancer (5250)
Cardiovascular disease (435)
Career advice (1720)
Career pathing (38)
CAR-T (292)
CDC (53)
Celiac Disease (2)
Cell therapy (787)
Cervical cancer (40)
Clinical research (70167)
Collaboration (1862)
Company closure (4)
Compensation (1247)
Complete response letters (70)
COVID-19 (2725)
CRISPR (98)
C-suite (956)
Cystic fibrosis (145)
Data (6908)
Decentralized trials (3)
Denatured (26)
Depression (152)
Diabetes (546)
Diagnostics (6815)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (284)
Drug pricing (193)
Drug shortages (29)
Duchenne muscular dystrophy (265)
Earnings (91027)
Editorial (60)
Employer branding (22)
Employer resources (153)
Events (118338)
Executive appointments (1023)
FDA (19845)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (28)
Funding (1589)
Gene editing (210)
Generative AI (49)
Gene therapy (650)
GLP-1 (1012)
Government (4708)
Grass and pollen (6)
Guidances (395)
Healthcare (18912)
HIV (72)
Huntington's disease (51)
IgA nephropathy (88)
Immunology and inflammation (268)
Immuno-oncology (79)
Indications (154)
Infectious disease (3032)
Inflammatory bowel disease (200)
Inflation Reduction Act (14)
Influenza (126)
Intellectual property (268)
Interviews (316)
IPO (16662)
IRA (50)
Job creations (3657)
Job search strategy (1433)
JPM (59)
Kidney cancer (18)
Labor market (92)
Layoffs (554)
Leadership (35)
Legal (7964)
Liver cancer (96)
Longevity (28)
Lung cancer (704)
Lymphoma (404)
Machine learning (52)
Management (59)
Manufacturing (899)
MASH (175)
Medical device (13836)
Medtech (13912)
Mergers & acquisitions (20080)
Metabolic disorders (1397)
mRNA (170)
Multiple sclerosis (171)
NASH (17)
Neurodegenerative disease (381)
Neuropsychiatric disorders (96)
Neuroscience (3108)
Neurotech (1)
NextGen: Class of 2026 (6530)
Non-profit (4528)
Now hiring (74)
Obesity (659)
Opinion (274)
Ovarian cancer (180)
Pain (222)
Pancreatic cancer (252)
Parkinson's disease (338)
Partnered (33)
Patents (547)
Patient recruitment (570)
Peanut (60)
People (59203)
Pharmaceutical (60)
Pharmacy benefit managers (32)
Phase 1 (21876)
Phase 2 (30892)
Phase 3 (23020)
Pipeline (6800)
Policy (304)
Postmarket research (2565)
Preclinical (9273)
Press Release (64)
Prostate cancer (272)
Psychedelics (50)
Radiopharmaceuticals (300)
Rare diseases (969)
Real estate (5965)
Recruiting (71)
Regulatory (24900)
Reports (54)
Research institute (2406)
Resumes & cover letters (353)
Rett syndrome (32)
RNA editing (18)
RSV (85)
Schizophrenia (159)
Series A (267)
Series B (198)
Service/supplier (11)
Sickle cell disease (104)
Special edition (23)
Spinal muscular atrophy (160)
Sponsored (44)
Startups (3627)
State (2)
Stomach cancer (18)
Supply chain (117)
Tariffs (89)
The Weekly (63)
Vaccines (1045)
Venture capital (98)
Weight loss (417)
Women's health (108)
Worklife (19)
Date
Last 7 days (603)
Last 30 days (2612)
Last 365 days (29928)
2026 (7356)
2025 (30212)
2024 (35254)
2023 (40117)
2022 (51214)
2021 (55748)
2020 (54105)
2019 (46582)
2018 (35071)
2017 (32159)
2016 (31521)
2015 (37586)
2014 (31363)
2013 (26367)
2012 (28578)
2011 (29263)
2010 (27328)
Location
Africa (740)
Alabama (88)
Alaska (7)
Arizona (328)
Arkansas (13)
Asia (39443)
Australia (6450)
California (12123)
Canada (3475)
China (1206)
Colorado (515)
Connecticut (515)
Delaware (362)
Europe (85223)
Florida (1826)
Georgia (387)
Hawaii (3)
Idaho (61)
Illinois (959)
India (77)
Indiana (551)
Iowa (22)
Japan (476)
Kansas (129)
Kentucky (44)
Louisiana (35)
Maine (73)
Maryland (1471)
Massachusetts (8662)
Michigan (344)
Minnesota (666)
Mississippi (6)
Missouri (136)
Montana (33)
Nebraska (29)
Nevada (133)
New Hampshire (82)
New Jersey (3225)
New Mexico (28)
New York (3187)
North Carolina (1538)
North Dakota (8)
Northern California (5992)
Ohio (359)
Oklahoma (22)
Oregon (41)
Pennsylvania (2444)
Puerto Rico (25)
Rhode Island (50)
South America (1115)
South Carolina (73)
South Dakota (1)
Southern California (4752)
Tennessee (199)
Texas (1895)
United States (42916)
Utah (362)
Vermont (1)
Virginia (288)
Washington D.C. (80)
Washington State (972)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
726,145 Results for "abbvie inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
AbbVie’s foray into the obesity space is successful so far, analysts agree, as amylin analog ABBV-295 elicited as much as 9.73% weight loss at 13 weeks in the multiple ascending dose portion of a Phase 1 trial.
March 9, 2026
·
2 min read
·
Heather McKenzie
Legal
AbbVie Sues HHS, CMS for Including Botox in Drug Price Negotiation Program
AbbVie contends that Botox should have been excluded from the IRA drug price negotiation program because it is a plasma-derived product.
February 12, 2026
·
1 min read
·
Tristan Manalac
Earnings
AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas
On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.
February 4, 2026
·
2 min read
·
Dan Samorodnitsky
Manufacturing
AbbVie Backs Obesity Push With $380M API Production Expansion Project in Illinois
Part of AbbVie’s vow to invest $100 billion in the U.S. over the next decade, the two Illinois facilities will make active ingredients for next-generation neuroscience and obesity drugs when they start operations in 2029.
February 24, 2026
·
2 min read
·
Nick Paul Taylor
C-suite
J&J, AbbVie CEOs See Pay Spike to More Than $30M
The chief executives of AbbVie and Johnson & Johnson are now among the highest-paid pharma leaders after pay bumps pushed their 2025 compensations past $30 million.
March 12, 2026
·
1 min read
·
Tristan Manalac
Psychedelics
AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing
Sales of Johnson & Johnson’s esketamine-based nasal spray jumped in the fourth quarter last year, priming the pump for a suite of other pharmas, including AbbVie, champing at the bit with their own psychedelics.
February 6, 2026
·
2 min read
·
Dan Samorodnitsky
Manufacturing
AbbVie Commits $100B in US R&D, Manufacturing, Winning Tariff, Pricing Exemptions
AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient basis. In exchange, the pharma secured exemptions from tariffs and other future pricing directives.
January 13, 2026
·
2 min read
·
Tristan Manalac
Cancer
AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market
The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.
January 12, 2026
·
2 min read
·
Nick Paul Taylor
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.
January 26, 2026
·
2 min read
·
Tristan Manalac
Cancer
JPM26: AbbVie Seeks Respect for Oncology Pipeline Following RemeGen Buy
Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.
January 14, 2026
·
2 min read
·
Heather McKenzie
1 of 72,615
Next
